Patents Assigned to Genentech, Inc.
  • Publication number: 20190112362
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 18, 2019
    Applicants: GENENTECH, INC., AC IMMUNE SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Publication number: 20190112361
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: September 24, 2018
    Publication date: April 18, 2019
    Applicants: GENENTECH, INC., AC IMMUNE SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Publication number: 20190112264
    Abstract: The invention provides compounds having the general formula I: (i) and pharmaceutically acceptable salts thereof, wherein the variables RA, RAA, subscript n, ring A, X2, L, subscript m, X1, ring B, R1, and RN have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
    Type: Application
    Filed: March 28, 2017
    Publication date: April 18, 2019
    Applicants: GENENTECH, INC., XENON PHARMACEUTICALS INC.
    Inventors: Sultan CHOWDHURY, Christoph Martin DEHNHARDT, Thilo FOCKEN, Michael Edward GRIMWOOD, Ivan William HEMEON, Steven MCKERRALL, Daniel SUTHERLIN
  • Publication number: 20190112368
    Abstract: Provided herein are methods of producing a polypeptide containing two chains, such as an antibody including a light chain and a heavy chain. In particular, methods are provided for producing heterologous secretory proteins in bacteria through utilization of optimized expression vectors and culture processes.
    Type: Application
    Filed: September 21, 2018
    Publication date: April 18, 2019
    Applicant: Genentech, Inc.
    Inventors: James GIULIANOTTI, Dorothea E. REILLY
  • Patent number: 10259808
    Abstract: Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n, p, q, r, X1, X2, X3, X4, Y, Z, A, Het, R1, R2, R3, R4, R5 R6, R7, R8, R9, R10, R11, R12 and R13 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of inflammatory diseases such as arthritis, muscular sclerosis and psoriasis.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: April 16, 2019
    Assignee: Genentech, Inc.
    Inventors: Benjamin Fauber, Emanuela Gancia, Tammy Ladduwahetty, David Vesey, Paul Winship, Olivier Rene
  • Patent number: 10258603
    Abstract: The present invention relates to compounds of formula (I): and to salts thereof, wherein R1, R2, Rc, and Rd have any of the values defined in the specification, and compositions and uses thereof. The compounds are useful as inhibitors of bromodomains. Also included are pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various bromodomain-mediated disorders.
    Type: Grant
    Filed: May 10, 2017
    Date of Patent: April 16, 2019
    Assignees: GENENTECH, INC., CONSTELLATION PHARMACEUTICALS, INC.
    Inventors: Brian K. Albrecht, Steven F. Bellon, Daniel J. Burdick, Alexandre Cote, Terry Crawford, Les A. Dakin, Vickie Hsiao-Wei Tsui, Michael Charles Hewitt, Yves LeBlanc, Steven R. Magnuson, Christopher G. Nasveschuk, F. Anthony Romero, Yong Tang, Alexander M. Taylor, Shumei Wang
  • Patent number: 10252005
    Abstract: Various embodiments disclosed herein relate to needle-based injectors that incorporate a power assembly comprising a stored energy source and a rate control assembly. The power assembly may be further configured to allow the injection to be performed with more force than a user may be capable of delivering, while also allowing the user to maintain control of the injection process after the stored energy source has been released and the injection has begun, such the user may increase or decrease the rate of injection, or stop the injection, during the injection process. In various embodiments, the power assembly may comprise spring- or gas-based stored energy sources, and/or may comprise friction- or tension-based rate control assemblies. Described herein are also methods for injecting an agent using embodiments of the devices described here.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 9, 2019
    Assignee: GENENTECH, INC.
    Inventors: Gordon D. Row, Andrew I. Poutiatine, Neal Schlatter, Adrian Bischoff
  • Publication number: 20190100530
    Abstract: The invention provides novel compounds having the general formula I: wherein R1, the A ring and the B ring are as described herein, pharmaceutical compositions including the compounds, and methods of using the compounds.
    Type: Application
    Filed: July 12, 2018
    Publication date: April 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Snahel PATEL, Gregory HAMILTON, Guiling ZHAO, Huifen CHEN, Blake DANIELS, Craig STIVALA
  • Publication number: 20190100578
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Application
    Filed: September 14, 2018
    Publication date: April 4, 2019
    Applicant: Genentech, Inc.
    Inventors: Vishva Dixit, Robert F. Kelley, Marissa L. Matsumoto
  • Patent number: 10246515
    Abstract: Provided herein are methods of using anti-LGR5 antibodies, for example, for treating a hedgehog-related disease including basal cell carcinoma.
    Type: Grant
    Filed: March 15, 2016
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Frederic J. De Sauvage, Brian Biehs
  • Patent number: 10246519
    Abstract: The invention provides NSP4 inhibitors (such as anti-NSP4 antibodies) and methods of using the same.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Shuo-Yen Jack Lin, Daniel K. Kirchhofer, Menno Van Lookeren Campagne
  • Patent number: 10246461
    Abstract: The invention relates generally to pharmaceutical tablet compositions comprising fumaric acid and the compound (S)-2-(3?-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4?-bipyridin]-2?-yl)-7,7-dimethyl-2,3,4,6,7,8-hexahydro-1H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1-one free base that is an inhibitor of Bruton's tyrosine kinase. The invention further relates to amorphous solid dispersions comprising at least one polymer and the Bruton's kinase inhibitor free base compound. The invention further relates to crystalline mesylate salts, crystalline chloride salts and crystalline sulfate salts of the Bruton's kinase inhibitor free base compound. In some aspects, the crystalline salts are single polymorphs.
    Type: Grant
    Filed: February 27, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Chen Mao, Dawen Kou, Po-Chang Chiang
  • Patent number: 10246518
    Abstract: The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
    Type: Grant
    Filed: December 11, 2017
    Date of Patent: April 2, 2019
    Assignee: Genentech, Inc.
    Inventors: Yongmei Chen, James Ernst, Hok Seon Kim, Junichiro Sonoda, Christoph Spiess, Scott Stawicki, Yan Wu
  • Publication number: 20190092829
    Abstract: The invention concerns inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23). The invention further concerns the use of IL-23 antagonists in the treatment of inflammatory diseases characterized by the presence of elevated levels of IL-17. IL-23 antagonists include, without limitation, antibodies specifically binding to a subunit or IL-17 or an IL-17 receptor. The invention additionally concerns induction of IL-7 production by using an IL-23 agonist.
    Type: Application
    Filed: April 19, 2018
    Publication date: March 28, 2019
    Applicant: Genentech, Inc.
    Inventor: Austin L. GURNEY
  • Patent number: 10240207
    Abstract: The present invention concerns cancer biomarkers. In particular, the invention concerns HGF as a biomarker for patient selection and patient prognosis in cancer, as well as methods of therapeutic treatment, articles of manufacture and methods for making them, diagnostic kits, methods of detection and methods of advertising related thereto.
    Type: Grant
    Filed: September 21, 2016
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Wei Yu, David Shames, Hartmut Koeppen, See Phan, Sandra Rost
  • Patent number: 10239947
    Abstract: The invention provides anti-CLL-1 antibodies and immunoconjugates and methods of using the same.
    Type: Grant
    Filed: July 24, 2017
    Date of Patent: March 26, 2019
    Assignee: Genentech, Inc.
    Inventors: Bing Zheng, Andrew Polson, Cecilia Chiu, Wei-Ching Liang, Yan Wu
  • Patent number: 10239858
    Abstract: Disclosed herein is a process of making a compound of formula I The compound of formula I is an inhibitor of MEK and thus can be used to treat cancer.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: March 26, 2019
    Assignees: EXELIXIS, INC., GENENTECH, INC.
    Inventors: Sriram Naganathan, Nathan Guz, Matthew Pfeiffer, C. Gregory Sowell, Tracy Bostick, Jason Yang, Amit Srivastava, Neel Kumar Anand
  • Publication number: 20190083643
    Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof, to pharmaceutical compositions containing them, and to their use in therapy for the prevention or treatment of cancer.
    Type: Application
    Filed: October 3, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Ho Huat Lee, Moana Tercel, John A. Flygare, Janet Gunzner-Toste, Thomas H. Pillow, Brian Safina, Leanna Staben, Vishal Verma, BinQing Wei, Guiling Zhao
  • Publication number: 20190085089
    Abstract: The invention provides anti-Ly6E antibodies, immunoconjugates and methods of using the same.
    Type: Application
    Filed: July 31, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Jyoti Asundi, Ron Firestein, Paul Polakis, Chie Sakanaka, Peter Chang, Rayna Takaki Venook
  • Publication number: 20190085094
    Abstract: Variant immunoglobulins with one or more amino acid modifications in the VH region that have altered binding to Staphylococcus aureus protein A, and methods of using the same are provided.
    Type: Application
    Filed: November 16, 2018
    Publication date: March 21, 2019
    Applicant: Genentech, Inc.
    Inventors: Yik Andy Yeung, Henry B. Lowman